Table 1.

Patients treated with tumour necrosis factor (TNF)‐α antagonists for vitiligo

Age (years)/sex	Disease treated	Vitiligo disease activity	Treatment regimen	TNF‐α antagonist dosing	Results	Report type	References
15–38/5 M, 1 F	Vitiligo	Progressive	Untreated for ≥ 3 months, then ETA (n = 2), IFX (n = 2), ADA (n = 2)	IFX: 5 mg kg−1 IV at weeks 0, 2, 6, then q8 wk. ETA: 50 mg SC 2 ×/wk. ADA: 80 mg SC at week 0, 40 mg SC at week 1, then 40 mg SC q2 wk	One worsened, five stabilized	PS	71
24–34/4 M	Vitiligo	Progressive	Untreated for 2 months, then ETA	50 mg SC 1 ×/wk for 12 weeks, then 25 mg 1 ×/wk for 4 weeks	Stabilized	PS	74
42/F, 46/F	Vitiligo	Progressive	Continued NB‐UVB and topical calcineurin inhibitors, added ETA	50 mg 2 ×/wk, then 50 mg 1 ×/wk for ≥ 1 year	Disease stabilization and repigmentation	PS	64

M, male; F, female; ETA, etanercept; IFX, infliximab; ADA, adalimumab; NB‐UVB, narrowband ultraviolet B; IV, intravenously; SC, subcutaneously; PS, pilot study; q2 wk, every 2 weeks; 2 ×/wk, two times per week.